Emerging treatment options for complicated skin and skin structure infections: Oritavancin.
Date of Publication
Clinical Medicine Insights: Therapeutics
Oritavancin is a semisynthetic lipoglycopeptide with in vitro activity against a variety of aerobic Gram-positive pathogens (including drug-resistant forms of staphylococci, streptococci, and enterococci) and select anaerobic organisms. Available published clinical efficacy and safety studies in humans to date focus primarily in the treatment of complicated skin and skin structure infections. While oritavancin doses in these studies varied, single daily doses of 200 mg (300 mg in patients > 100 kg) for 3–7 days have demonstrated efficacy similar to comparators (such as vancomycin followed by cephalexin). The most frequent adverse events reported to date include gastrointestinal complaints, insomnia, dizziness, itching, and rash. Further safety and efficacy data are needed to better define its potential place in therapy.
Pound, M. W.; Drew, R. H.; Wilson, D.; and Townsend, M. L., "Emerging treatment options for complicated skin and skin structure infections: Oritavancin." (2011). Pharmacy Practice. 647.